Introduction
Acute autonomic and sensory neuropathy is characterized by autonomic and sensory impairment without motor dysfunction that reaches its peak severity within a short period of time (Colan et al., 1980) . The character of its progression is similar to that of Guillain-Barré syndrome. Since the first clear description by Colan et al. in 1980 , such cases have been only anecdotally reported (Fagius et al., 1983; Senda et al., 1986; Tohgi et al., 1989; Kanda et al., 1990; Pavesi et al., 1992; Yasuda et al., 1995; Bennett et al., 1996; Adachi et al., 1998; Kurokawa et al., 1998) . Due to the rarity of this disorder, the spectrum of its clinical and pathological features, including the severity of autonomic and sensory impairment, has not yet been clarified.
From the point of view of the autonomic neuropathy with monophasic, acute or subacute progression, at least three subgroups have been proposed on the basis of the concomitance or absence of sensory or motor dysfunctions: (i) pure autonomic neuropathy (Young et al., 1969 (Young et al., , 1975 , (ii) autonomic neuropathy with sensory impairment (Colan et al., 1980) and (iii) autonomic neuropathy with sensory and motor impairment (Yokota et al., 1994) , although there could be some overlap. In these forms, acute neuropathy characterized by profound autonomic and sensory dysfunction and preserved motor function has been designated as acute autonomic and sensory neuropathy (Colan et al., 1980) . However, it has not been determined whether these forms should be, nosologically, clearly divided into independent categories or whether they belong to a spectrum of autonomic neuropathy. Indeed, in the previous reports of acute autonomic and sensory neuropathy, patients with slight impairment of motor dysfunction were also included (Tohgi et al., 1989) . In addition, the relationship of these forms to Guillain-Barré syndrome, associated with autonomic and sensory impairment, has not yet been clarified.
The form of pure autonomic neuropathy has been established as an isolated nosological entity, as autoimmune autonomic ganglionopathy since the discovery of anti-ganglionic acetylcholine receptor antibodies (Vernino et al., 2000 (Vernino et al., , 2008 . In autoimmune autonomic ganglionopathy, 50% of cases are positive for anti-ganglionic acetylcholine receptor antibodies (Vernino et al., 2008) . Before the establishment of autoimmune autonomic ganglionopathy, it was reported as acute pandysautonomia, autoimmune autonomic neuropathy, idiopathic autonomic neuropathy or subacute autonomic neuropathy (Vernino et al., 2000 (Vernino et al., , 2008 Klein et al., 2003) . As ganglionic acetylcholine receptor is located only in the sympathetic, parasympathetic and enteric autonomic ganglia, autoimmune autonomic ganglionopathy is considered to show autonomic dysfunction without sensory and motor impairment (Vernino et al., 2008) . However, some early reports noted mild sensory disturbances, such as numbness, and a reduction of small myelinated fibres in sural nerve biopsy specimens in cases with acute pandysautonomia or acute pandysautonomic neuropathy (Appenzeller et al., 1973; Low et al., 1983; Feldman et al., 1991) . According to a recent review of autoimmune autonomic ganglionopathy, 25% of patients reported minor sensory symptoms, although objective sensory impairment was not present (Vernino et al., 2008) . Whether these cases should be considered as autoimmune autonomic ganglionopathy or acute autonomic and sensory neuropathy has not been determined. Furthermore, the long-term prognosis of acute autonomic and sensory neuropathy has not been clarified, as well as whether the prognostic features of acute autonomic and sensory neuropathy are different from those of autoimmune autonomic ganglionopathy or other autonomic neuropathies.
In this study, we assessed 21 patients with acute autonomic and sensory neuropathy, including an autopsy case. We address the mode of progression, spectrum of sensory symptoms, pathological features in relation to the neuropathic symptoms, prognosis and the nosological entity in the spectrum of autonomic neuropathies.
Methods Patients
We retrospectively investigated patients with acute autonomic and sensory neuropathy who were referred to our institutions from 1982 to 2008. Acute autonomic and sensory neuropathy in the present study was defined as neuropathy with monophasic progression of the autonomic and sensory symptoms and signs, in the absence of muscle weakness (Colan et al., 1980) . Preserved motor function was confirmed by nerve conduction studies, except for Patient 3, whose general condition was poor throughout the course of the disease and who died 2 years later. Patients with abnormal motor conduction velocity, distal latency or compound muscle action potential values were not included. We investigated the medical records of our institutions and found 25 patients diagnosed with acute autonomic and sensory neuropathy. However, we excluded 2 of these patients because slight motor involvement was recorded. We excluded 2 further patients due to a lack of detailed medical records in the initial phase of neuropathy. Patients underwent clinical and neurological assessment, routine blood and urine studies, and cerebrospinal fluid analysis. Neurological examinations were performed repetitively by at least two neurologists. The presence of somatic neuropathy was clinically defined by the presence of sensory signs and a reduction or absence of deep tendon reflexes without pathological reflexes. Sensory examinations were performed for pinprick, temperature, light touch, vibratory sensation and joint position sensation. A positive Romberg's sign or pseudoathetosis in the upper extremities was designated as sensory ataxia. The degrees of sensory impairment for each modality, spontaneous pain and sensory ataxia, were categorically scaled as 0 for none, 1+ for mild, 2+ for moderate and 3+ for severe. For sensory ataxia, patients were designated as severe if they could not detect the position of their extremities and could not move their limbs without observing them. Muscle strength was assessed with manual muscle testing. Autonomic involvement was characterized in terms of abdominal symptoms, urination, orthostatic symptoms, pupillary response and sweating. The presence or absence of clinically obvious landmarks such as vomiting, diarrhoea or constipation for dysfunction of the digestive system, dysuria or urinary retention needing catheterization for urinary dysfunction, syncope or orthostatic hypotension for orthostatic intolerance, mydriasis for pupillary dysfunction and dryness of the skin on palpation for hypohidrosis/anhidrosis was assessed by bedside examinations of the patients, reviewing the patients' records and interviewing the patients' families. Urinary symptoms were estimated by nocturnal or diurnal urinary frequency, a sensation of urgency, urinary incontinence, voiding difficulty and retention. Constipation was considered to be present if there were no stools for 43 days. Orthostatic hypotension was defined as a fall of at least 30 mmHg in the systolic blood pressure within 10 min of rising from a supine position. It was assessed using the head-up tilt test unless the general condition of the patient was unsuitable. The area of abnormal sweating was confirmed using Minor's iodine-starch test in Patients 5, 6, 12-14 and 19 (Kumazawa et al., 1993) . The 'peak phase' of neuropathy was defined as the time point when the autonomic dysfunction, superficial sensory impairment and deep sensory impairment all reached their peak severity.
A detailed history was obtained from each patient, as well as from their families, concerning lifestyle, occupation, diet and the amount of alcohol consumed daily. Patients with underlying diseases that may cause autonomic dysfunction or somatic neuropathy were excluded. These included diabetes mellitus, amyloidosis, Sjö gren's syndrome, Fabry disease and chronic alcoholism (Koike et al., 2006) . Part of the clinical aspects of Patients 2, 5-9 and 12 were described earlier (Sahashi et al., 1985; Senda et al., 1986; Yasuda et al., 1995; Adachi et al., 1998; Fukada et al., 2004) . Spinal MRI was performed using a 1.5 T unit. We used axial T 2 *-weighted gradient echo images as described earlier (Yasuda et al., 1994; Sobue et al., 1995; Mori et al., 2001) . Antibodies that bind to neuronal ganglionic acetylcholine receptor were examined in the laboratory of Dr Steven Vernino (Vernino et al., 2000) .
Intravenous immunoglobulin (IVIg; 400 mg/kg for 5 days), plasma exchange or high-dose IV methylprednisolone (1000 mg/day for 3 days for adults, 30 mg/kg/day up to 1000 mg/day for 3 days for children) alone or in combination were administered to patients other than Patients 7, 19 and 21.
Assessment of functional status
The patients' functional status was assessed at the peak phase according to the modified Rankin scale (van Swieten et al., 1988) : 0 = asymptomatic; 1 = non-disabling symptoms not interfering with lifestyle; 2 = minor disability from symptoms leading to some restriction of lifestyle, but not interfering with the patients' capacity to care for themselves; 3 = moderate disability from symptoms significantly interfering with lifestyle or preventing an independent existence; 4 = moderately severe disability from symptoms clearly precluding independent existence, although not requiring 24 h attention from a caregiver and 5 = severe disability and total dependence, requiring constant attention.
Electrophysiological assessment
Motor and sensory conduction were measured in the median, tibial and sural nerves, using a standard method with surface electrodes for stimulation and recording (Kimura et al., 1989a, b) . Motor conduction was investigated in the median and tibial nerves, recording from the abductor pollicis brevis and abductor hallucis brevis, respectively. The following nerve segments were used for calculating motor conduction velocity: wrist to elbow for the median nerve, and ankle to popliteal fossa for the tibial nerve. Sensory conduction was investigated in the median and sural nerves. These were recorded antidromically using ring electrodes at the second digit for the median nerve and bar electrodes at the ankle for the sural nerve. Normal control values were based on a previously published report . Values that deviated from the mean AE 2 SD of these controls were defined as abnormal.
Pathological assessment of sural nerve biopsy specimens A sural nerve biopsy was performed in 12 patients as described earlier (Sobue et al., 1989; Koike et al., 2003 Koike et al., , 2007 . The specimens were divided into two portions. The first was fixed in 2.5% glutaraldehyde in 0.125 M cacodylate buffer (pH 7.4) and embedded in epoxy resin for morphometric and ultrastructural studies. The density of myelinated fibres was assessed in toluidine blue-stained semi-thin sections using a computer-assisted image analyser (Luzex FS; Nikon, Tokyo, Japan), and the density of small and large myelinated fibres was calculated as described earlier (Sobue et al., 1989 (Sobue et al., , 1990 Koike et al., 2008b) . Clusters of two or more small myelinated fibres enclosed by one basement membrane were designated as an instance of axonal sprouting Hattori et al., 2003) . For the electron microscopy study, epoxy resin-embedded specimens were cut into ultra-thin transverse sections and stained with uranyl acetate and lead citrate. To assess the density of unmyelinated fibres, electron micrographs were taken at a magnification of Â4000 in a random fashion to cover the area of ultra-thin sections as described earlier (Koike et al., , 2008b . These electron micrographs were enlarged to Â6500. Unmyelinated axons were distinguished from Schwann cell cytoplasmic profiles by their round or oval shape, a lighter appearance and a higher number of microtubules (Behse et al., 1975; Jacobs et al., 1985) . The presence of mesaxon-like structures and a greater density of the axolemma than that of the membrane of the Schwann cells were also used to identify unmyelinated axons (Ochoa et al., 1967; Behse et al., 1975) . A fraction of the glutaraldehyde-fixed sample was processed for a teased-fibre study and the pathological condition was microscopically assessed according to the criteria described earlier (Sobue et al., 1989; Dyck et al., 1993) . The second portion of the specimen was fixed in 10% formalin solution and embedded in paraffin. Sections were cut by routine methods and stained with haematoxylin and eosin, Congo red, the Klü verBarrera method and the Masson trichrome method. Control values were based on a previously published report (Koike et al., 2008b) .
Pathological assessment of the autopsied cases
An autopsy was performed in two patients (Patients 1 and 2), one of which was systematically examined. In Patient 2, the nervous system including the brain, spinal cord, ventral and dorsal roots of C5, Th7 and L4, dorsal root ganglia from Th7, thoracic sympathetic ganglia and other visceral organs were removed, fixed in 10% formalin solution and embedded in paraffin. The tissues were cut and stained as described for the sural nerve specimens (Sobue et al., 1989 (Sobue et al., , 1990 Koike et al., 2004) . The median nerve from the axilla to the wrist and the sciatic/tibial nerve from the upper thigh to above the medial malleolus were also removed and fixed in 1.5% glutaraldehyde, 3% formalin and 0.05 M phosphate buffer (pH 7.4). After fixation, samples were embedded in paraffin as well as epoxy resin, and cut and stained as described for the sural nerve specimens. Portions of the ventral and dorsal spinal roots were also fixed in 2.5% glutaraldehyde in 0.125 M cacodylate buffer (pH 7.4) and processed in the same manner. In Patient 1, distal portions of the median and sural nerves were removed at autopsy and processed as biopsy specimens.
Statistical analyses
Quantitative data were presented as the mean AE SD. Statistical analyses were performed using the 2 -test, the Mann-Whitney U-test or Spearman's rank correlation analysis, as appropriate. P-values 50.05 were considered to indicate significance.
Results

Clinical course and symptoms
Patients consisted of 6 males and 15 females, aged 29.0 AE 14.9 years (Table 1) . Some sort of antecedent event was reported in 15 patients shortly before the initiation of neuropathy. Of these, 13 patients experienced symptoms indicating an antecedent infection including an upper respiratory tract infection, such as a cough or a sore throat, or a gastrointestinal tract infection, such as diarrhoea accompanied by fever. Patient 19 had an abortion and Patient 21 reported a skin eruption mimicking urticaria 10 and 2 days, respectively, before the initial symptoms of neuropathy. Patient 2 was in the third trimester of pregnancy and underwent a caesarean section 3 days after the onset of the disease. The initial symptoms of neuropathy in our series were numbness or pain in the extremities or trunk or those related to autonomic dysfunction. The initial symptoms in 9 patients were those related to the gastrointestinal tract, such as vomiting, abdominal distention or diarrhoea. As these patients initially visited a department of digestive disease, their referral to the neurological department tended to be late. Patient 19 underwent abdominal surgery due to severe ileus. Patients 1-3 were in an intensive care unit at the time of first referral to neurologists, as they were in a critical condition. In all patients, sensory impairment was predominant with respect to pinprick, temperature and light touch sensations (i.e. superficial sensation) in the initial phase. Although sensory impairment was restricted to superficial sensation in some patients, the impairment of vibration and joint sensations (i.e. deep sensation) subsequently appeared in the others. Along with the loss of proprioceptive and kinaesthetic sensation, sensory ataxia appeared. Patients with severe sensory ataxia (Patients 1-6) could not move their limbs without observing them because they could not detect the position of their extremities. Overall, the duration from the onset to the peak phase of neuropathy ranged from 6 to 25 (13.5 AE 6.2) days. The severity of the sensory ataxia tended to become worse as the duration to the peak phase became longer (P50.001, Fig. 1 ). On the other hand, superficial sensory impairment and autonomic dysfunction tended to become widespread and considerably severe in a short period, irrespective of the presence or absence of sensory ataxia. The details of the autonomic and sensory manifestations at the peak phase of neuropathy are listed in Table 2 . The autonomic manifestations were widespread and severe, affecting the sympathetic and parasympathetic functions. Disturbances of the digestive system were serious in most patients; 9 patients showed a severe reduction of peristalsis manifesting as paralytic ileus. Sixteen patients needed urethral catheterization ascribable to neurogenic flaccid bladder. Orthostatic hypotension was detected in 18 of the 19 patients examined. Seventeen of these patients frequently suffered from blackout and syncope while attempting to sit up or rise from the bed. Mydriasis without the absence of light reflex was observed bilaterally in 13 patients and unilaterally in 2 patients. Hypohidrosis or anhidrosis was present in the whole body of 18 patients, while it was spared in the face of 2 and observed in only the trunk of 1. The distribution of sensory deficits included the proximal regions of the limbs, face, scalp and trunk in most patients (Fig. 2) . It tended to be asymmetrical and segmental rather than presenting as a symmetric polyneuropathy. Patchy areas with minor or no sensory deficit were conspicuous in the trunk and face in some patients. Both superficial and deep sensations were affected more or less in 14 patients (Patients 1-14). Twelve of these patients (Patients 1-12) manifested signs indicating sensory ataxia, such as a positive Romberg's sign or pseudoathetosis in the hands. Conversely, the other seven patients (Patients 15-21) manifested only superficial sensory deficit without deep sensory impairment. The duration from the onset to the peak phase of neuropathy was significantly longer in patients with sensory ataxia than in those without (16.7 AE 5.6 versus 8.8 AE 3.1 days, P50.01). The absence of deep tendon reflexes tended to be observed in patients with sensory ataxia rather than in those without. All but one patient reported spontaneous pain. Evoked Table 1 a Assessed by T 2 *-weighted gradient echo image.
b MRI was performed in the initial phase of neuropathy (ninth day from the onset of neuropathy). c Accompanied by fever.
pain was also conspicuous in many of the patients. In Patient 14, the physician could not examine the deep tendon reflexes in the upper extremities because even a light touch evoked severe pain.
As for the other symptoms, attacks of coughing induced by a sense of discomfort in the pharynx, phonation or deglutition were observed in 9 patients (Table 1) . Coughing episodes were so severe in Patient 11 that they induced vomiting and she had difficulty with oral intake during the initial phase. Tenderness of muscles or myalgia was reported in six patients. Psychiatric symptoms with unstable mental status including depression, hysteria or character changes, such as the tendency to act in a childish manner, were observed in 13 patients. Difficulty in communication due to deep sensory impairment in the tongue and extremities take an emotional toll especially on patients with severe sensory ataxia. Sleep apnoea was present in four patients who manifested severe sensory ataxia. As generalized convulsion due to hypoxaemia frequently occurred in Patient 2, non-invasive intermittent positive pressure support was needed. Patient 6 also needed mechanical ventilator support. Seven patients experienced aspiration pneumonia because of the difficulty in swallowing due to oral, pharyngeal and respiratory tract sensory impairment. Twelve patients 8, 10, 13, 15, 17, 19 and 20) were administered total parenteral nutrition due to paralytic ileus or dysphasia caused by sensory deficit in the oropharyngeal region. Patients 1-3 needed a tracheostomy due to severe dysphasia and repetitive aspiration. (days) Duration from onset to peak phase Figure 1 The severity of sensory ataxia and the duration to the peak phase of neuropathy. The severity of sensory ataxia tended to become worse as the duration to the peak phase became longer (P50.001, Spearman's rank correlation analysis). 0, none; 1, mild; 2, moderate and 3, severe. Deep tendon reflexes; A = absent; Ac = Achilles tendon; B = biceps tendon; N = normal; P = patellar tendon; R = reduced. 0, 1 + , 2+ and 3+ represent none, mild, moderate and severe involvement for sensory deficits, respectively. Symptoms and signs were assessed at the peak phase of neuropathy. a Not determined due to a critical condition. b Not determined due to severe hyperesthaesia.
Illustrative cases Autonomic neuropathy with impairment of all sensory modalities
Patient 1, a 55-year-old male, was previously healthy except for hypertension. On the day of onset, he suffered from lower abdominal pain and distention. On the second day, he was referred to a department of gastroenterological medicine and admitted to hospital. At that time, the findings from a CT scan of the abdomen, gastroscopy and an air contrast barium enema did not reveal any abnormalities except for markedly reduced peristalsis. On the third day, he felt numbness on the ulnar side of his right and left upper limbs. On the morning of the sixth day after the onset, he noted a difficulty with urination. On the eighth day, he became febrile and began to complain of respiratory discomfort. He vomited frequently because his abdominal distention became severe. He fell into respiratory failure shortly after that and was transferred to the intensive care unit. On admission, examination showed anisocoria, loss of the pharyngeal reflex, marked reduction of pinprick and touch sensation in the ulnar side of the bilateral upper extremities and below the Th10 level of the spinal dermatome, loss of deep tendon reflexes in the four extremities, bilateral flexor plantar responses, loss of perspiration in the trunk and extremities, preserved vibration and joint sensations and normal muscle strength. Abdominal distention was remarkable on X-ray and bowel sounds were absent (Fig. 3) . X-ray of the chest showed bilateral severe pneumonia. Endotracheal intubation was performed and he was put on a respirator. A bronchoscope revealed large amounts of vomit in the bronchus. The coughing reflex was not induced during these procedures. He was referred to the neurological department on the 10th day. On examination, he was alert. The right pupil showed marked mydriasis and no light reflex, and the light reflex in the left pupil was also diminished. Other cranial nerves showed no obvious abnormalities except for the absence of the pharyngeal reflex. Loss of pinprick, temperature and light touch sensations were present in the whole trunk and four extremities, while the reduction of vibration and joint sensations was detected only in the third to the fifth fingers of both hands and the right lower limb. On the basis of the diagnosis of acute autonomic and sensory neuropathy, he was administered IVIg (400 mg/kg for 5 days). On the 11th day, sensory ataxia was noted in the four extremities in spite of the initiation of IVIg therapy. On the 13th day after onset, the area of sensory deficit extended to the right half of the face. On the 14th day, he began to show emotional instability, i.e. continual irritation, anger, frustration and, occasionally, hyperventilation attacks. On the 16th day, his neuropathic symptoms reached their peak severity. The sensory deficit extended to the whole body. Spontaneous pain was also reported throughout the whole body. The bilateral pupils showed marked mydriasis with no light reflex. The neurological manifestations observed at that time are shown in Table 2 . On the 21st day, he was weaned from the ventilatory support but his spontaneous respiration sometimes arrested for $1 min during sleeping. He could not leave the hospital because almost no improvement was observed during the course of the disease. He died of sepsis 2 years and 3 months later.
Autonomic neuropathy with predominant loss of superficial sensation
Patient 17, a 27-year-old previously healthy female, reported a sore throat and fever 6 days before admission to the hospital. Numbness in the upper limbs subsequently appeared. She began Figure 2 The distribution of superficial sensory deficit in individual patients. It included the proximal regions of the limbs, tongue, face, scalp and trunk in most patients and tended to be asymmetrical and segmental, rather than presenting as a symmetric polyneuropathy. Patchy areas with minor or no sensory deficit were conspicuous in the trunk and face in some patients. The shaded areas represent those of superficial sensory deficit, while the non-shaded areas are where there is preserved sensation.
to complain of faintness upon standing and 3 days later complained of 'dimness' in her eyes. On the fourth day from onset, she suffered severe diarrhoea and felt numbness in the face and tongue. Neurological examination on the day of admission revealed bilateral mydriasis with an absent light reflex and the loss of the pharyngeal reflex. Oral intake was impossible; she vomited with a belch as soon as she swallowed liquids or foods. Superficial sensation was severely reduced, while deep sensation was normal in the four extremities and the trunk. Sensory ataxia was not observed. Mild spontaneous pain was reported in the whole body. Muscle strength was well preserved. Deep tendon reflexes were not reduced in the upper and lower extremities at that time. Sweating was markedly decreased over the whole body. Urethral catheterization was required due to urinary retention. Blood pressure was 150 mmHg systolic and 100 mmHg diastolic in the supine position, and immediately dropped to 80 and 40 mmHg, respectively, upon standing. Diarrhoea had stopped after she was admitted, while constipation continued thereafter. On the eighth day, a slight reduction of the deep tendon reflexes was detected. She became unable to remain seated due to the appearance of syncope. The neurological manifestations observed on the eighth day are described in Table 2 . After that day, her symptoms were at their peak severity and a slight improvement was observed 1 month later. Oral intake became narrowly possible. Urinary catheterization was not needed one and a half months later. IVIg (400 mg/kg for 5 days) administered 50 days from onset did not appear to alter her clinical course. Two months from onset, she was able to sit on a seat due to the improvement of orthostatic hypotension and sweating was observed on her back. Four months later, she was discharged from hospital. However, she was almost wheelchair bound and her diet was restricted to porridge or blended food. Five months later, she suffered aspiration pneumonia and was hospitalized again. At that time, mydriasis was still present but the light reflex was slightly observed. An improvement of the sensory deficits was not observed. Electrocardiography performed 7 months from onset showed an improvement of the coefficient of variation of the R-R intervals to 4.19% from 1.95% at the peak phase. One year after onset, she was able to walk at home, but experienced blackouts almost every day. She reported no further improvements in her symptoms for another year.
Laboratory features
Nerve conduction studies revealed the reduction of sensory nerve action potentials with the preservation of sensory conduction velocities (Table 1) . Sensory nerve action potentials were evoked significantly less often in patients with sensory ataxia than in those without (P50.01 for the median and sural nerves). Sensory nerve action potentials in the patients with sensory ataxia and in those without were 1.6 AE 3.6 and 31.3 AE 20.0 mV for the median nerve and 0.8 AE 2.6 and 8.8 AE 7.1 mV for the sural nerve, respectively. Conversely, sensory conduction velocities were preserved in evoked patients (58.7 AE 6.0 m/s for the median nerve and 52.1 AE 5.1 m/s for the sural nerve). Somatosensory evoked potentials were recorded in nine patients (Patients 4-9, 12, 14 and 16) using stimulation of the median nerve at the wrist (Kachi et al., 1994; Mori et al., 2001 Mori et al., , 2005 . Cortical (N20), cervical (N13) and Erb's point (N9) peaks were elicited in Patients 9 and 14, while these peaks were not elicited in the other patients. MRI was performed in 15 patients. It showed a high-intensity area in the posterior column in 4 patients with obvious sensory ataxia (Table 1) . In Patients 4, 5 and 8, high-intensity areas tended to be widespread, ranging from the cervical and thoracic to the lumbar spinal cord, including both the fasciculi cuneatus and gracilis (Fig. 4) . The high-intensity area was restricted to the fasciculus cuneatus in the upper cervical to lower thoracic spinal cord in Patient 9. Although Patients 1 and 11 manifested sensory ataxia, we did not detect a high-intensity area in the posterior column. MRI was performed in the initial phase of neuropathy in Patient 1. In Patient 11, sensory ataxia was mild, and functional recovery was good. In patients without sensory ataxia but with superficial sensory deficits, a high-intensity area was not detected in the posterior column.
An elevation of CSF protein levels without an increase in cell count was found in all patients (Table 1) . Titres for anti-ganglionic acetylcholine receptor antibodies were examined in 6 patients (Patients 1, 2, 4, 9, 17 and 20) and were negative in all. Although anti-ganglioside antibodies were screened in 10 patients (Patients 2, 9-11, 14-18 and 21), pathologically significant antibodies were not found.
The results for the autonomic testing are summarized in Supplementary material. Abnormalities were detected in 9 of 11 patients for the coefficient of variation of the R-R intervals on electrocardiography, 11 of 12 patients for plasma levels of norepinephrine, 9 of 9 patients for pupillary response to the application of cholinergic and adrenergic agents, 4 of 5 patients for blood pressure response to norepinephrine infusion, 3 of 3 patients for salivary secretion, 6 of 7 patients for lacrimal secretion, 7 of 7 patients for urodynamic study, 5 of 6 patients for myocardial 123 I-metaiodobenzylguanidine uptake and 2 of 2 patients for perspiration measured by the capacitance hygrometric technique following an intradermal injection of cholinergic agents.
Pathological findings of the sural nerve
Sural nerve biopsies revealed axonal neuropathy without evidence of demyelinating changes in all cases examined (Table 3) . On light microscopic observation, all cases, except Patient 1, had a significant reduction of myelinated fibres. The ratio of small to large myelinated fibres was significantly less than normal control values (0.70 AE 0.48 versus 1.66 AE 0.25, respectively, P50.01), suggesting the tendency of predominant small-fibre loss especially in cases without sensory ataxia (Fig. 5A) . Axonal sprouting, suggestive of regenerative fibres, was not evident in any case, including a second biopsy from Patient 6, which was performed 3 years later. On electron microscopy, unmyelinated fibres were severely reduced in most patients (Fig. 5B) . Clusters of small unmyelinated fibres, suggestive of regenerating fibres, were not observed in any patients.
In Patient 1, a biopsy was performed before the neuropathic symptoms progressed to the peak phase. Although accumulation of organelles and ballooning of axons were occasionally seen, myelinated fibre density in this patient seemed to be preserved (Fig. 5C ). Teased-fibre preparations showed axonal degeneration in 13% of fibres. Conversely, the unmyelinated fibre density was preserved with no apparent morphological abnormalities suggestive of unmyelinated axon damage. The contralateral sural nerve was obtained at autopsy from this patient. This specimen showed a severe reduction of myelinated and unmyelinated fibres (Fig. 5D ).
Pathological findings in the autopsied case
Autopsy was systematically performed in Patient 2, who had severe autonomic and all-modality sensory impairment and died 11 months after onset. Severe depletion of myelinated fibres in the posterior cervical, thoracic and lumbar spinal roots was evident (Fig. 6A) , while myelinated fibres were preserved in the anterior cervical, thoracic and lumbar spinal roots (Fig. 6B ). Neurons were depleted and Nageotte's nodules were abundant in the thoracic dorsal root ganglia (Fig. 6C ). On a cross section of the spinal cord, the lateral and ventral areas showed a normal appearance, while the dorsal tracts were heavily damaged due to loss of myelinated fibres (Fig. 6D) . The anterior horn cells were preserved in appearance, and central chromatolysis was not observed in these cells (Fig. 6E ). There was a severe reduction of neuronal cells in the thoracic sympathetic ganglia (Fig. 6F) ; however, we also observed preserved neuronal cells in another segment of sympathetic ganglion, suggesting that the degree of neuronal cell loss is highly variable among the spinal segments of sympathetic ganglia (Fig. 6G) . As for the parasympathetic nervous system, neuronal cells in Auerbach's plexus in the gastrointestinal tract were severely reduced. Lymphocytic infiltration was not apparent in the peripheral nervous system. A remarkable multifocal patchy distribution of myelinated fibres was observed along the length of the median and sciatic/tibial nerves. These remaining clustered myelinated fibres had a large diameter. Axonal sprouts were not evident in any portion. The distal portion of the median nerve was also obtained at autopsy in Patient 1. A patchy distribution of large myelinated fibres and an absence of axonal sprouting were also observed (Fig. 6H) . Examination of the skeletal muscles showed an almost normal appearance in both patients. These findings indicate that the patchy distribution of myelinated fibres in the nerve trunk resulted from the depletion of sensory nerve fibres and the preservation of motor nerve fibres.
Treatment and functional recovery
IVIg, plasma exchange or IV methylprednisolone alone or in combination were administered to most patients (Table 4 ). In the majority of patients who were administered IV methylprednisolone, prednisone (1 mg/kg/day) was subsequently given orally. Patients 18 and 21 were treated with oral prednisone alone after the neuropathy reached its peak phase. As the diagnosis of neuropathy tended to be late, treatment was initiated before the neuropathy reached its peak phase in 11 patients. Seven patients reported the cessation of progression during or soon after the initiation of treatment. In the distal portion of the median nerve, the patchy distribution of surviving large myelinated fibres, suggestive of depletion of sensory nerve fibres and preservation of motor nerve fibres, was observed. Cross section. Toluidine blue stain. Scale bars = 20 mm (A and B), 100 mm (C, E and H) and 50 mm (F and G).
administered to Patient 20 41 month after the neuropathy reached its peak phase, a relief of pain was noted in this patient. Three patients (Patients 1-3) died within 3 years from onset due to sepsis. In the other patients, gradual recovery, especially that of autonomic symptoms, was observed within several months (Table 4) . Sensory deficits tended to persist for a long time and compromise activities of daily living. For example, loss of pain and temperature sensations slightly recovered but only in patchy areas. Sensory ataxia also persisted for long periods. Conversely, pain was considerably ameliorated in many of the patients although it was a common and serious symptom, and often refractory to symptomatic pain management in the early phase. However, Patients 4-6, who were followed up for 410 years, still suffered from severe pain over most of their bodies. The functional status assessed by the modified Rankin scale was 4.6 AE 0.7 at the peak phase, 2.9 AE 1.4 at 1 year and 2.5 AE 1.3 at 2 years. The follow-up period in patients who survived for 43 years was 7.3 AE 5.7 years, and the modified Rankin scale at the last assessment was 1.9 AE 1.0 (Table 5) .
Discussion
In the present study, we described the clinicopathological features of patients with acute autonomic and sensory neuropathy. Similar patients have been only anecdotally reported as case reports because of the rarity of this disease. For the first time, we evaluated a large number of patients and were able to examine the mode of progression, spectrum of sensory symptoms, pathological features in relation to neuropathic symptoms and prognosis of acute autonomic and sensory neuropathy. Our patients were separated from Guillain-Barré syndrome due to the absence of motor dysfunction (Asbury et al., 1990) . Some of the patients showed only a superficial sensory deficit as their sensory manifestation, while others manifested involvement of all sensory modalities resulting in sensory ataxia. Previous reports of typical acute autonomic and sensory neuropathy cases also described sensory ataxia (Fagius et al., 1983; Tohgi et al., 1989; Yasuda et al., 1995; Adachi et al., 1998) , while reports of patients with selective or predominant superficial sensory loss are also present (Pavesi et al., 1992; Bennett et al., 1996; Kurokawa et al., 1998) . One may argue that our series included two categories of neuropathy; patients with all modalities of sensory deficit including deep sensation, and those with selective superficial sensory deficit. In our patients, the superficial sensory impairment and autonomic dysfunction became widespread and severe in a relatively short period of time irrespective of the presence or absence of sensory ataxia. Conversely, signs of deep sensory impairment appeared later and gradually progressed with time. Patients with sensory ataxia showed only superficial sensory impairment and autonomic dysfunction in the initial phase. Therefore, neuropathic symptoms in the initial phase of these patients were similar to those in patients with selective superficial sensory deficit. Sensory ataxia appeared thereafter and its severity became worse as the duration of + = present; À = absent; IVIg = intravenous immunoglobulin; IVMP = intravenous methylprednisolone; ND = not determined; OI = oral intake; PE = plasma exchange; TF = tube feeding; TPN = total parenteral nutrition. a According to a previous report (van Swieten et al., 1988) . b Not determined because the patients were bedridden. c Prednisone was orally administered after the neuropathy reached its peak phase.
progression was lengthened, as shown in Fig. 1 and in the case description of Patient 1. The mode of progression in which certain symptoms appear and evolve with time may suggest that the presence or absence of sensory ataxia could reflect the severity or expansion of the disease process. Two-thirds of patients had an antecedent event, including upper respiratory or gastrointestinal tract infection that mimicked Guillain-Barré syndrome, suggesting that immune-mediated mechanisms are responsible for the aetiology of acute autonomic and sensory neuropathy. High protein levels in the CSF without an increase in cell count and the effect of immunomodulatory treatment also support this view. The pattern of sensory involvement tended to be similar to that of ganglionopathy rather than polyneuropathy (Dyck et al., 1992; Grant et al., 1997; Gorson et al., 2008 ). An autopsy case revealed the loss of nerve cell bodies in the thoracic sympathetic and dorsal root ganglia and Auerbach's plexus. These findings suggest that the mainstay of the lesion in our patients is located in the autonomic and sensory ganglia. Previous autopsy cases with acute autonomic and sensory neuropathy also support this view (Fagius et al., 1983; Tohgi et al., 1989) . Unlike previously reported cases with immune-mediated ganglionopathy, lymphocytic infiltration was not apparent in our cases (Griffin et al., 1990; Dyck et al., 1992; Mori et al., 2005) . Such a finding may have already disappeared because 1 year had passed since the first symptom of neuropathy. The high-intensity area in the posterior column of the spinal cord on the MRI was suggestive of the presence of lesions in the central rami as well as the peripheral rami of the sensory neurons; the scarcity of regenerating fibres on the sural nerve biopsy specimens and incomplete or sometimes poor recovery are also compatible with ganglionopathy (Mori et al., 2005) . We have to take into consideration that the sural nerve biopsy findings may not reflect the neuropathic features when the specimens were obtained in the early phase of the disease. This discrepancy is caused by a delay in the appearance of morphological changes indicating axonal degeneration, especially those of unmyelinated fibres. Conversely, specimens obtained in the later phase reflected the neuropathic features of the preferential impairment of autonomic functions and superficial sensation as a predominant loss of small fibres.
Sensory ganglionopathies are known to occur in various aetiologies (Onishi et al., 1974; Grant et al., 1997; Kusunoki et al., 1999; Kuntzer et al., 2004; Brannagan et al., 2005; Mori et al., 2005; Oki et al., 2007; Gorson et al., 2008; Windebank et al., 2008) . Patients with Sjö gren's syndrome and paraneoplastic syndrome may manifest sensory ataxia due to a preferential involvement of large-diameter sensory neurons in the dorsal root ganglia (Ohnishi et al., 1986; Griffin et al., 1990; Kusunoki et al., 1999; Mori et al., 2005; Kaida et al., 2008) . Conversely, recent reports suggest that ganglionopathy may preferentially affect small-diameter neurons (Koike et al., 2008a) . Such ganglionopathy has been reported in an autopsy case with Fabry disease (Onishi et al., 1974) . In addition, series of idiopathic cases and those associated with Sjö gren's syndrome, paraneoplastic syndrome and coeliac disease with suspected ganglionopathy and superficial sensory impairment have also been reported (Brannagan et al., 2005; Mori et al., 2005; Oki et al., 2007; Gorson et al., 2008) . In our patients, the initial manifestations were those exclusively related to autonomic or superficial sensory impairment. Deep sensory impairment appeared later and became progressively more severe over time. The clinical course in our patients may suggest that small neurons in the autonomic and sensory ganglia are affected in the initial phase of acute autonomic and sensory neuropathy and large neurons in sensory ganglia are subsequently involved. In this context, acute autonomic and sensory neuropathy may belong to a spectrum of another form of ganglionopathy with the preferential involvement of small sensory neurons and autonomic neurons. Immune-mediated sensory neuropathy may also affect the posterior spinal roots (Sinnreich et al., 2004) . Demyelinating changes are conspicuous in such neuropathy, while such changes were not seen in our cases.
As for the effect of treatment, we should exhibit caution when determining its efficacy because of the monophasic nature of this disease. As autonomic symptoms, especially abdominal symptoms, were predominant in the majority of patients in the initial phase, the patients tended to be seen first in a gastroenterological department. The neuropathic symptoms in such patients had already become severe at the time of their referral to the neurological department. Although 11 patients underwent some sort of immunomodulatory treatment, including IVIg and plasma exchange, during the progression of neuropathy, the neuropathic symptoms still progressed in some of these patients. These patients tended to have severe symptoms; therefore, they may have needed repetitive therapy. On the other hand, progression in other patients may have ceased because of treatment, although we cannot deny the possibility that this finding simply reflected the natural course of the disease process. As we consider acute autonomic and sensory neuropathy to be a ganglionopathy, functional recovery may be unfavourable once the autonomic and sensory neurons are depleted. The improvement was attributable to the recovery of autonomic functions, while sensory deficits tended to persist for a long time. Preserved nerve fibres, especially unmyelinated fibres, of a sural nerve biopsy specimen in spite of obvious autonomic and sensory deficits in Patient 1 may indicate the presence of the period of dysfunction before actual neuronal cell loss. This may explain, to some extent, the clinical recovery in our patients, especially the autonomic symptoms. In addition, the complicated networks of the autonomic nervous system may compensate for the autonomic functions.
In the spectrum of autonomic neuropathy, a concept of autoimmune autonomic ganglionopathy has recently been established in association with anti-acetylcholine receptor antibodies (Vernino et al., 2000 (Vernino et al., , 2008 . Although the presence of an antecedent event, the monophasic nature of the clinical course and ganglionopathy being a putative mechanism are similar to our acute autonomic and sensory neuropathy cases, the presence of obvious sensory involvement and the negative titres of anti-acetylcholine receptor antibodies indicate that our cases are distinct from autoimmune autonomic ganglionopathy. We compared our 21 acute autonomic and sensory neuropathy patients with the 18 previously reported autoimmune autonomic ganglionopathy patients with positive anti-acetylcholine receptor antibodies (Klein et al., 2003) (Table 6 ). This result showed significant differences in the frequency of an antecedent event (P50.05), age (P50.0001) and progression (P50.0001). Autoimmune autonomic ganglionopathy may show a slowly progressive clinical course resembling pure autonomic failure (Klein et al., 2003; Sandroni et al., 2009; Koike et al., 2010) .
Psychiatric changes, including character changes, were seen in our patients. These may be, in part, attributable to severe sensory impairment including painful sensation. On the other hand, a previous report of acute autonomic and sensory neuropathy suggested the involvement of the central nervous system (Inoue et al., 1989) . Lymphocytic infiltration in the central nervous system was reported in a patient with pandysautonomia and sensorimotor deficits (Stoll et al., 1991) . In our series, Patient 2 developed the syndrome of inappropriate antidiuretic hormone and amenorrhea in addition to character changes; Patient 12 showed similar tendencies. The syndrome of inappropriate antidiuretic hormone has also been reported in association with other immune-mediated neuropathies (Ellison et al., 2007; Iorio et al., 2009) . Further studies are needed to clarify whether organs other than the peripheral nervous system are concomitantly involved in acute autonomic and sensory neuropathy.
